OncoSELECT: A Blood Test to Identify Targeted and Hormone Therapies in All Types of Solid Cancers
ONCODNA HAS ANNOUNCED THE LAUNCH OF ITS TARGETED LIQUID BIOPSY TEST ONCOSELECT. THIS FAST AND MINIMALLY INVASIVE BIOMARKER TEST AIMS TO HELP CLINICIANS OPTIMIZE TREATMENT STRATEGIES ACROSS ALL PATIENTS DIAGNOSED WITH A STAGE 3 OR STAGE 4 SOLID TUMOR.
Biopsy usually involves removing solid tissue for examination using a needle, computed tomography or surgical intervention. These procedures carry inherent risks for the patient, such as infection and complications due to tumor location, as well as diagnostic risks, such as insufficient material or sampling bias due to tumor heterogeneity. To avoid these complications, liquid biopsy has become a very interesting alternative as it can rapidly identify clonal evolution and the development of treatment resistance.
By targeting a panel covering SNVs, Indels, gene translocations, unusual splicing and TERT promoter, OncoSELECT aims to support clinical decisions by increasing the chances of matching patients with targeted therapy, hormone therapy and potential clinical trials.
WHEN IS ONCOSELECT USEFUL?
• When a patient cannot have a tumor biopsy, when their tumor tissue sample is too old or too scarce for comprehensive biomarker testing.
• When a clinician needs to be informed on their patient’s response to a chemotherapy in neoadjuvant settings.
• When a patient relapses under current treatment and there is a need to determine if they developed resistance mutations.
• When a clinician needs to assess the heterogeneity of the patient’s disease to increase the chances of choosing the best treatment.
WHY SHOULD ONCOSELECT BE USED IN CLINICAL PRACTICE?
Precision medicine in oncology is advancing fast. With OncoSELECT, OncoDNA pursues its efforts to help oncologists optimize treatment strategies across all advanced solid tumors and improve patients’ clinical outcomes.
OncoSELECT is available worldwide for clinical use, except in the US where it is available for research purposes only.